Table 3A

 Relative risk including 95% confidence intervals (CIs) and observed number of cancers of selected haematopoietic sites by time of follow up in the Swedish Inpatient Register RA cohort 1990–2003. Relative risks comparing the cohort with the Swedish general population, adjusting for age, sex, and calendar period

Site (ICD code)No observed, relative risk (95% CI) by time with RA*
No1–4 yearsNo5–9 yearsNo10+ years
*Counting from date of first discharge listing RA.
CLL, chronic lymphocytic leukaemia.
All haematopoietic malignancies1291.5 (1.2 to 1.8)981.5 (1.2 to 1.8)1541.5 (1.3 to 1.7)
Malignant lymphoma including CLL801.6 (1.2 to 1.9)681.7 (1.3 to 2.2)1021.7 (1.4 to 2.0)
Plasma cell neoplasms140.9 (0.5 to 1.5)70.6 (0.2 to 1.2)130.7 (0.4 to 1.1)
Leukaemia excluding CLL301.9 (1.3 to 2.7)211.7 (1.1 to 2.7)382.0 (1.4 to 2.8)
    Acute lymphatic leukaemia11.5 (0.0 to 8.2)00.0 (0.0 to 7.1)00.0 (0.0 to 4.5)
    Acute myeloid leukaemia192.2 (1.3 to 3.5)121.8 (0.9 to 3.2)222.1 (1.3 to 3.2)
    Chronic myeloid leukaemia21.2 (0.1 to 4.4)43.2 (0.9 to 8.1)73.6 (1.5 to 7.5)
    Other or undefined leukaemia81.7 (0.7 to 3.4)51.4 (0.5 to 3.3)81.4 (0.6 to 2.8)
Polycytaemia vera51.5 (0.5 to 3.5)20.8 (0.1 to 2.8)10.2 (0.0 to 1.3)